Skip to main content
SpringerLink
Log in

Osteoporosemittel

  • Chapter
Arzneiverordnungs-Report 2013

Zusammenfassung

Grundlage der Behandlung der Osteoporose sind nichtmedikamentöse Maßnahmen und eine ausreichende Zufuhr von Calcium und Vitamin D als Basistherapie (Rizzoli et al. 2008). Bei niedrigem Frakturrisiko reichen sie zur Prophylaxe von osteoporotischen Frakturen aus. Ab einem 10-Jahresfrakturrisiko von 30% ist eine spezifische Osteoporosetherapie indiziert (Dachverband Osteologie 2009). Sie stützt sich auf den Einsatz der knochenabbauhemmenden Antiresorptiva (Bisphosphonate, Raloxifen, Denosumab) und der knochenaufbaufördernden Osteoanabolika (Strontiumranelat, Teriparatid, Parathormon) (Übersicht bei Rachner et al. 2011). Strontiumranelat hat sowohl antiresorptive als auch osteoanabole Eigenschaften. Östrogene sind nach der aktuellen Risikobewertung und entsprechenden Leitlinien nur noch zur Osteoporoseprävention zugelassen, wenn andere Mittel unverträglich oder kontraindiziert sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der Deutschen Ärzteschaft (2008): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 2. Auflage. Im Internet: www.akdae.de/35/83_Osteoporose_2008_2Auflage.pdf

  • Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004): Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525.

    Article  PubMed  CAS  Google Scholar 

  • Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM (2007): Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438–441.

    Article  PubMed  CAS  Google Scholar 

  • Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010): Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341: c3691.

    Article  PubMed  Google Scholar 

  • Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004): Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199.

    Google Scholar 

  • Brancaccio D, Cozzolino M (2007): Lanthanum carbonate: time to abandon prejudices? Kidney Int 71: 190–192.

    Article  PubMed  CAS  Google Scholar 

  • Brown JE, Coleman RE (2012): Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 9: 110–118.

    Article  PubMed  CAS  Google Scholar 

  • Compston J (2009): Recent advances in the management of osteoporosis. Clin Med 9: 565–569.

    Article  PubMed  Google Scholar 

  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial (2009): Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756–765.

    Google Scholar 

  • Dachverband Osteologie (2009): DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Langfassung Osteologie 18: 304–324.

    Google Scholar 

  • Drüeke TB (2007): Lanthanum carbonate as a first-line phosphate binder: the „cons“. Semin Dial 20: 329–332.

    Article  PubMed  Google Scholar 

  • Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S (2011): Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 26: 1303–1312.

    Article  PubMed  CAS  Google Scholar 

  • Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA (2008): Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res 23: 112–120.

    Article  PubMed  CAS  Google Scholar 

  • Favia G, Pilolli GP, Maiorano E (2009): Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45: 406–413.

    Article  PubMed  CAS  Google Scholar 

  • Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al.; Women’s Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669–683.

    Google Scholar 

  • Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JP, Pieger CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial (2007): Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1810.

    Google Scholar 

  • Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M (2007): Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867–2878.

    Article  PubMed  Google Scholar 

  • Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004): The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–486.

    Article  PubMed  CAS  Google Scholar 

  • Mousny M, Bouse X, Wise L, Everett ET, Hancock R, Vieth R, Devogelaer JP, Grynpas MD (2006): The genetic influence on bone susceptibility to fluoride. Bone 39: 1283–1289.

    Article  PubMed  CAS  Google Scholar 

  • NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942–1948.

    Google Scholar 

  • Pazianas M, Compston J, Huang CL (2010): Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 25: 2–10.

    Article  PubMed  CAS  Google Scholar 

  • Rachner TD, Khosla S, Hofbauer LC (2011): Osteoporosis: now and the future. Lancet 377: 1276–1287.

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Bruyère O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP (2009): Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45: 1059–1064.

    Article  PubMed  CAS  Google Scholar 

  • Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (2008): The role of calcium and vitamin D in the management of osteoporosis. Bone 42: 246–249.

    Article  PubMed  CAS  Google Scholar 

  • Sainz M, del Pozo JG, Arias LH, Carvajal A (2009): Strontium ranelate may cause alopecia. BMJ 338: 1494–1498.

    Article  Google Scholar 

  • Seeman E, Devogelaer J-P, Lorenc R, Spector T, Brixeu K, Balogh A, Stucki G, Reginster JY (2008): Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23: 433–438.

    Article  PubMed  CAS  Google Scholar 

  • Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research (2010): Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267–2294.

    Google Scholar 

  • Silverberg SJ, Fairman C, Bilezikian JP et al. (2004): Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma (abstract no. SA495). J Bone Miner Res 19 Suppl. 1: S103.

    Google Scholar 

  • Straub DA (2007): Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 22: 286–296.

    Article  PubMed  Google Scholar 

  • Suki W, Zabaneh R, CangianoJ, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S (2006): A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 21 (Suppl 4): 145–146.

    Google Scholar 

  • Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012): Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50: 870–875.

    Article  PubMed  Google Scholar 

  • Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570–577.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Im Neuenheimer Feld 366, 69120

    Prof. Dr. med. Ulrich Schwabe

  2. Heidelberg, Mozartstraße 20, 69121

    Prof. Dr. med. h.c. Reinhard Ziegler

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. h.c. Reinhard Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Schwabe, U., Ziegler, R. (2013). Osteoporosemittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation